Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metyrapone Addition in Resistant Depression with DST Non-suppression
NCT03491696Phase 4Unknown
- Sponsor
- Centre Hospitalier de Rouffach
- Start
- Dec 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of metyrapone in major depressive disorder (MDD), sponsored by Centre Hospitalier de Rouffach. Primary endpoint: Blood cortisol rate during a Dexamethasone Suppression Test at Day 29. Status: unknown.
02
Drugs
metyrapone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03491696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491696.